Company News: J&J nixes production of heart stent, Sanofi pairs with Audion

Share this article:

Johnson & Johnson company Cordis has announced that it will discontinue the development of the Nevo Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies that are more in patient demand. Cordis will also halt production of Cypher and Cypher Select Plus Sirolimus-Eluting Coronary Stents by the end of 2011, according to a release.

Recently rebranded big pharma Sanofi has announced a two-year research partnership with biopharma company Audion Therapeutics with the objective of developing potential treatments for hearing loss. The collaboration will utilize technology developed at the Massachusetts Eye and Ear Infirmary – one of the world's leading research facilities devoted to the study of hearing and deafness – for the optimization of small molecules by using a regenerative medicine approach.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.